HIMSS
To address Europe’s most pressing healthcare challenges, Europe's longest-running, most influential digital health conference returns in 2024, bringing together innovators to shape tomorrow’s healthcare.
The HIMSS24 European Health Conference & Exhibition will occur from 29-31 May at the Centro Congressi Roma La Nuvola in Rome, Italy. The conference will be the epicenter for pan-European collaborations and innovation, featuring thought leaders and healthcare professionals working together to create the best technology solutions across the digital health landscape.
HIMSS24 Europe will feature programming focused on major global health challenges. Experts will lead discussions on how Europe uses data analytics, artificial intelligence, cybersecurity, and other cutting-edge technologies to address universal issues like health equity, patient privacy, access to care, workforce burnout, staffing shortages, and climate change.
Registration is open for HIMSS24 Europe, and interested journalists can contact HIMSS to receive complimentary press credentials. The conference will attract thousands of industry experts worldwide, including CIOs and CTOs, AI experts, cybersecurity leaders, data scientists, healthcare practitioners, and public health policy leaders.
“We’ve built an innovative programme that offers the tools and insights healthcare professionals need to transform systems and improve outcomes,” said Ronan O’Connor, Managing Director, EMEA and Vice President at HIMSS. “This year, we are proud to bring executives, policymakers, and healthcare professionals of all kinds together in Italy, which is a leader in digital health innovation.”
The program lineup includes a deep dive into Europe’s current regulatory landscape, including the AI Act, the European Health Data Space (EHDS), and the European Recovery and Resilience Fund. This year’s keynote speakers will lend their expertise to enrich discussions on pressing healthcare issues.
- Marco Marsella, director, Digital, EU4Health and Health Systems Modernisation and DG SANTE, European Commission.
- Hela Ghariani, co-head of the Digital Health Delegation, Ministry of Social Affairs and Health, France and co-chair of the EU eHealth Network.
- John Riggi, FBI veteran and national advisor for cybersecurity and risk at the American Hospital Association
- Sharon Allen, co-founder and chief executive officer of World Telehealth Initiative, a remote philanthropic model that allows physicians to provide sustainable medical expertise via telehealth.
- Dr. Waheed Arian, founder of Arian Wellbeing.
Emerging topics such as the ethical use of AI in healthcare and finding the balance between effective data sharing and protecting patient privacy will be top of mind for presenters and attendees.
The conference will showcase emerging healthcare solutions through Startup Pitchfest, offering a platform for innovative startups to address entrenched challenges faced by health systems and providers.
The conference programming is supported by a Programme Committee comprising 17 highly reputable and well-respected healthcare professionals from across Europe.
Networking opportunities and interactive experiences will also be at the forefront of HIMSS24 Europe, where attendees can connect with representatives from more than 70 countries representing the global health ecosystem.
Click here to learn more about HIMSS24 Europe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424984367/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 21:36:00 CET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom